Primecap Management Co. CA Sells 371,850 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Primecap Management Co. CA decreased its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) by 52.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 336,300 shares of the medical instruments supplier’s stock after selling 371,850 shares during the period. Primecap Management Co. CA owned 0.45% of OraSure Technologies worth $1,214,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Raymond James Financial Inc. bought a new position in OraSure Technologies in the fourth quarter valued at approximately $37,000. Atom Investors LP acquired a new stake in shares of OraSure Technologies in the 3rd quarter valued at approximately $49,000. US Bancorp DE grew its stake in shares of OraSure Technologies by 310.4% in the fourth quarter. US Bancorp DE now owns 19,433 shares of the medical instruments supplier’s stock valued at $70,000 after buying an additional 14,698 shares in the last quarter. Intech Investment Management LLC acquired a new position in OraSure Technologies during the third quarter worth $84,000. Finally, Aigen Investment Management LP bought a new stake in OraSure Technologies during the fourth quarter worth $76,000. Institutional investors and hedge funds own 93.50% of the company’s stock.

Insider Buying and Selling at OraSure Technologies

In related news, CFO Kenneth J. Mcgrath purchased 64,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were acquired at an average price of $3.15 per share, for a total transaction of $201,600.00. Following the purchase, the chief financial officer now owns 371,013 shares in the company, valued at approximately $1,168,690.95. This represents a 20.85 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director John P. Kenny purchased 47,659 shares of the stock in a transaction on Thursday, February 27th. The stock was bought at an average cost of $3.17 per share, for a total transaction of $151,079.03. Following the completion of the acquisition, the director now owns 70,915 shares in the company, valued at approximately $224,800.55. This trade represents a 204.93 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 190,284 shares of company stock valued at $600,348 in the last quarter. 3.40% of the stock is currently owned by insiders.

OraSure Technologies Trading Up 1.4 %

Shares of NASDAQ OSUR opened at $3.51 on Thursday. The company has a market capitalization of $262.55 million, a P/E ratio of 23.40 and a beta of -0.02. OraSure Technologies, Inc. has a 12 month low of $2.69 and a 12 month high of $6.69. The stock has a 50 day moving average of $3.72 and a 200-day moving average of $3.92.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.